中国药物经济学评价指南的应用与挑战

发布时间：2018-03-15 05:10

本文选题：药物经济学　切入点：中国药物经济学评价指南　出处：《中国药学杂志》2017年13期 　论文类型：期刊论文

【摘要】：目的分析中国药物经济学评价指南的应用现状和主要挑战。方法梳理中国卫生政策对药物经济学的需求,分析中国药物经济学研究和指南应用现状,对国际上主要国家或地区药物经济学指南的应用和发展情况进行汇总。结果在中国医药卫生决策方面,药物经济学评价及其证据在新药研发、药品定价、医保支付及临床合理用药方面将发挥重要作用。由于《中国药物经济学评价指南》是专家建议指南,而非政府强制使用,加之中国缺乏开展高质量药物经济学研究的临床和流行病学基础数据,使得其在实际应用中遇到了诸多困难和挑战,远未发挥其应有的作用。结论基于国际经验和中国实际,建议国家强制或鼓励药物经济学评价指南在医疗卫生和医保决策中发挥作用;建议成立药物经济学评价的国家认证机构;建议定期更新和补充指南内容;同时加强临床、合理用药、药物流行病、生命质量等基础性研究。
[Abstract]:Objective to analyze the current situation and main challenges of pharmacoeconomics evaluation guidelines in China. Methods to analyze the demand of Chinese health policies for pharmacoeconomics, and to analyze the current situation of pharmacoeconomics research and application in China. The application and development of the guidelines on pharmacoeconomics in major countries or regions in the world are summarized. Results in China's pharmaceutical and health decision-making, the evaluation of pharmacoeconomics and its evidence are in the research and development of new drugs and the pricing of drugs. Health insurance payments and rational clinical use will play an important role. Because the guidelines for the Evaluation of Pharmacoeconomics in China are recommended by experts rather than compulsory use by the government. In addition, the lack of basic clinical and epidemiological data for the development of high-quality pharmacoeconomics in China makes it meet with many difficulties and challenges in its practical application, and it is far from playing its due role. It is recommended that national guidelines for evaluation of pharmacoeconomics be enforced or encouraged to play a role in decision-making on health and health care; the establishment of a national certification body for pharmacoeconomic evaluations; the recommendation that the content of the guidelines be regularly updated and supplemented; and the strengthening of clinical practices, Rational use of drugs, drug epidemics, quality of life and other basic research.
【作者单位】：中国人民解放军第306医院药学部;北京大学中国卫生经济研究中心;美国辛辛那提大学药学院;
【分类号】：R956

【参考文献】